In this article, we are going to take a look at where Denali Therapeutics, Inc. (NASDAQ:DNLI) stands against other biotech stocks with the biggest upside potential. While 2024 was a “challenging ...

This is an increase of 22 owner(s) or 4.95% in the last quarter. Average portfolio weight of all funds dedicated to DNLI is 0.15%, a decrease of 14.17%. Total shares owned by institutions ...

Investors in Denali Therapeutics Inc (Symbol: DNLI) saw new options begin trading this week, for the December 19th expiration. One of the key inputs that goes into the price an option buyer is ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

DNLI stock opened at $13.27 on Monday. Denali Therapeutics has a 1-year low of $10.57 and a 1-year high of $33.33. The stock has a market capitalization of $1.93 billion, a P/E ratio of -4.81 and ...

Denali Therapeutics, Inc. (NASDAQ:DNLI) shares traded higher on Wednesday after the company initiated its biologics license application (BLA) for the accelerated approval of Tividenofusp Alfa for ...

Shares of Denali Therapeutics DNLI gained 11.8% on Wednesday after the company announced that it has initiated a rolling submission of a biologics license application (BLA) for accelerated ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...